TGF-β1 inhibits expression and activity of hENT1 in a nitric oxide-dependent manner in human umbilical vein endothelium

Cardiovascular Research

Volumn 82, Issue 3, 2009, Pages 458-467

  Vega, José L ^a   Puebla, Carlos ^a   Vásquez, Rodrigo ^a   Farías, Marcelo ^a   Alarcón, Julio ^b   Pastor Anglada, Maral ^c   Krause, Bernardo ^a   Casanello, Paola ^a   Sobrevia, Luis ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DEL BÍO BÍO   (Chile)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adenosine; Endothelium; Human; Membrane; Nitric oxide; TGF 1; Transport

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; CARRIER PROTEINS AND BINDING PROTEINS; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; KT 5823; MESSENGER RNA; N ACETYL S NITROSOPENICILLAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROTEIN SLC29A1; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; PROTEIN SERINE THREONINE KINASE; SLC29A1 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN; WESTERN BLOTTING; CELL CULTURE; FEMALE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PREGNANCY; PREGNANCY COMPLICATION; PROMOTER REGION; VASCULAR ENDOTHELIUM; VASODILATATION;

ADENOSINE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; NITRIC OXIDE; PREGNANCY; PREGNANCY COMPLICATIONS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1; VASODILATION;

EID: 66249130069     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp045     Document Type: Article

References (43)

1. Smits P, Williams SB, Lipson DE, Banitt P, Rogen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans.Circulation 1995;92:2135-2141.
2. Costa F, Biaggioni I. Role of nitric oxide in adenosine-induced vasodilation in humans. Hypertension 1998;31:1061-1064.
3. Riksen NP, Rongen GA, Yellon D, Smits P. Human in vivo research on the vascular effects of adenosine. EurJ Pharmacol 2008;585:220-227.
4. Vásquez G, Sanhueza F, Vásquez R, González M, San Martín R, Casanello P et al. Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical endothelium. J Physiol 2004;560:111-122.
5. Casanello P, Escudero C, Sobrevia L Equilibrative nucleoside (ENTs) and cationic amino acid (CATs) transporters: implications in foetal endothelial dysfunction in human pregnancy diseases. Curr Vasc Pharmacol 2007;5: 69-84.
6. Fox SB, Khong TY. Lack of innervation of human umbilical cord. An immunohistochemical study. Placenta 1990;11:59-62.
7. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004;447:735-743.
8. Burnstock G. Vessel tone and remodeling. Nat Med 2006;12:16-17.
9. Escudero C, Sobrevia L A hypothesis for preeclampsia: adenosine and inducible nitric oxide synthase in human placental microvascular endothelium. Placenta 2008;29:469-483.
10. Farías M, San Martín R, Puebla C, Pearson JD, Casado JF, Pastor-Anglada M et al. Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol 2006;208:451-460.
11. Puebla C, Farías M, González M, Vecchiola A, Aguayo C, Krause B et al. High D-glucose reduces SLC29A1 promoter activity and adenosine transport involving specific protein 1in human umbilical vein endothelium. J Cell Physiol 2008;215:645-656.
12. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.Nat Med 1997;3: 89-93.
13. McGinn S, Poronnik P, King M, Gallery ED, Pollock SA. High glucose and endothelial cell growth: novel effects independent of autocrine TGF-beta 1 and hyperosmolarity.Am J Physiol Cell Physiol 2003;284: C1374-C1386.
14. Vásquez R, Farías M, Vega JL, San Martín R, Vecchiola A, Casanello P et al. D-Glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium. J Cell Physiol 2007;212:626-632.
15. Saura M, Zaragoza C, Cao W, Bao C, Rodriguez-Puyol M, Rodriguez-Puyol D et al. Smad2 mediates transforming growth factor-beta induction of endothelial nitric oxide synthase expression. Circ Res 2002;91:806-813.
16. Valdés R, Fernandes-Veledo S, Aymerich I, Casado FJ, Pastor-Anglada M. TGF-beta transcriptional activates the gene encoding the high-affinity adenosine transporter CNT2 in rat liver parenchymal cells. Cell Mol Life Sci 2006;63:2527-2537.
17. Lygnos MC, Pappa KI, Papadaki HA, Relakis C, Koumantakis E, Anagnou NP et al. Changes in maternal plasma levels of VEGF, bFGF, TGF-beta1, ET-1 and sKL during uncomplicated pregnancy, hypertensive pregnancy, and gestational diabetes. In Vivo 2006;20:157-163.
18. Yener S, Demir T, Akinci B, Bayraktar F, Kebapcilar L, Ozcan MA et al. Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus. Diabetes Res Clin Pract 2007;76:193-198.
19. Flores L, Naf S, Hernaez R, Conget I, Gomis R, Esmatjes E. Transforming growth factor beta at clinical onset of Type 1 diabetes mellitus. A pilot study. Diabet Med 2004;21:818-822.
20. Azar ST, Salti I, Zantout MS, Major S. Alterations in plasma transforming growth factor beta in normoalbuminuric type 1 and type 2 diabetic patients. J Clin Endocrinol Metab 2000;85:4680-4682.
21. Meeking DR, Cummings MH, Thorne S, Donald A, Clarkson P, Crook JR et al. Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria. Diabet Med 1999;16:841-847.
22. Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial.JAMA 2007;298:1539-1547.
23. Rose JB, Coe IR. Physiology of nucleoside transporters: back to the future. Physiology 2008;23:41-48.
24. Casanello P, Torres A, Sanhueza F, González M, Farías M, Gallardo V et al. Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium.Circ Res 2005;97:16-24.
25. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003;284:R1-R12.
26. Ogonowski AA, Kaesemeyer WH, Jin L, Ganaphaty V, Leibach FH, Caldwell RW. Effects of NO donors and synthase agonist on endothelial cell uptake of L/arg and superoxide production.Am J Physiol Cell Physiol 2000;278:C136- C143.
27. Grider JR, Jin JG. Vasoactive intestinal peptide release and L-citrulline production from isolated ganglia of the myenteric plexus: evidence for regulation of vasoactive intestinal peptide release by nitric oxide. Neuroscience 1993;54:521-526.
28. Rojas S, Rojas R, Lamperti L, Casanello P, Sobrevia L. Hyperglycaemia inhibits thymidine incorporation and cell growth via protein kinase C, mitogen-activated protein kinases and nitric oxide in human umbilical vein endothelium. Exp Physiol 2003;88:209-219.
29. Devés R, Boyd CA. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 1998;78:487-545.
30. 2B adenosine receptors in placenta microvascular endothelial cells from preeclampsia. Placenta 2008;29:816-825.
31. Farré X, Guillen-Gómez E, Sánchez L, Hardisson D, Plaza Y, Lloberas J et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 2004;112:959-966.
32. Gratz A, Jose J. Protein domain library generation by overlap extension (PDLGO): a tool for enzyme engineering. Anal Biochem 2008;378: 171-176.
33. Puebla C. Transcriptional regulation of SLC29A1 promoter gene of equilibrative nucleoside transporter type 1 (hENT1) by D-glucose in human fetal endothelium. Santiago de Chile: Pontificia Universidad Católica de Chile; 2008 (Thesis).
34. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-2942.
35. Dong YL, Vegiraju S, Chauhan M, Gangula PR, Hankins GD, Goodrum L et al. Involvement of calcitonin gene-related peptide in control of human fetoplacental vascular tone. Am J Physiol Heart Circ Physiol 2004;286:H230-H239.
36. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-264.
37. Wyatt AW, Steinert JR, Wheeler-Jones CP, Morgan AJ, Sugden D, Pearson JD et al. Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J 2002;16:1584-1594.
38. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294- 4301.
39. Agrotis A, Kalinina N, Bobik A. Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr Vasc Pharmacol 2005;3:55-61.
40. Botella LM, Rodriguez-Sanz F, Komi Y, Fernandez-L A, Varela E, Garrido-Martin EM et al. TGF-beta regulates expression of KLF6 and its splice variants, and promotes cooperative transactivation of common target genes through a Smad3/Sp1/KLF6 interaction. Biochem J 2008; doi:10.1042/BJ20081434.
41. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schönfeld C et al. HIF-1 -dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 2005;202:1493- 1505.
42. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ. TGF-beta coordinately activates TAK1 /MEK/AKT/NFκB and SMAD pathways to promote osteoclast survival. Exp Cell Res 2008;31:2725-2738.
43. Todorovic-Rakovic N, Ivanovic V, Demajo M, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D. Elevated plasma levels of TGFbeta1 in patients with locally advanced breast cancer related to other clinical stages. Arch Oncol 2003;11:131-133.